Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: A comprehensive functional retinal assessment

Research output: Contribution to journalArticle

Abstract

Purpose: To explore functional retinal changes in neovascular AMD patients (nAMD) treated with ranibizumab 0.5 mg combined with photodynamic therapy (PDT) 3 days after the first injection in the long term. Methods: Patients with no prior treatment for nAMD were treated with 3 injections of ranibizumab 0.5 mg 1 month apart and a single session of standard PDT 3 days after the first injection. Best-corrected visual acuity and time-domain OCT at baseline and every 28 ± 2 days were performed; microperimetry at 3, 6, and 12 months and multifocal electroretinogramm (mfERG) at 3 and 12 months were repeated. Fluorescein angiography and vision-related quality-of-life questionnaire were performed at baseline and 12 months. Results: 12/15 nAMD patients completed the 12 months study and received an average of 3.4 ± 0.7 injections. Mean VA changed from 54.67 ± 15.72 to 59.0 ± 24.77 letters (p = 0.371), while mean retinal sensitivity from 5.5 ± 4.8 to 6.6 ± 6.0 dB (p = 0.216). MfERG N1-P1 response amplitude densities (RADs) were significantly different from baseline (p <0.01) in the central 0 -2.5, whereas in the peripheral retinal areas (2.5 -20), not significant (p > 0.01) changes in N1-P1 RADs were detected. The "general vision" VFQ-25 subscale showed a statistically significant improvement at 3 and 12 months. Conclusions: Ranibizumab 0.5 mg combined with standard PDT 3 days after the first injection determines an improvement of mfERG values in the retinal central area in nAMD patients in long-term follow-up.

Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalDocumenta Ophthalmologica
Volume127
Issue number3
DOIs
Publication statusPublished - Dec 2013

    Fingerprint

Keywords

  • Age-related macular degeneration
  • Anti-VEGF
  • Choroidal neovascular membrane
  • mfERG
  • Photodynamic therapy
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Physiology (medical)

Cite this